Abstract
Identified as the prototype of ‘atypicality’, clozapine heralded a new generation of antipsychotics intent on providing greater efficacy than ‘typical’ antipsychotics, while diminishing the risk of D2-related side effects such as extrapyramidal symptoms and hyperprolactinemia. Ziprasidone is the most recent in this new class of antipsychotics to enter the clinical market.